Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1993-9-27
pubmed:abstractText
1. Neurotransmitters released from nerve endings are inactivated by re-uptake into the presynaptic nerve terminals and possibly into neighbouring glial cells. While analysing the functional properties of alpha 1-adrenoceptors in the hypothalamus, we observed a high-affinity uptake process for noradrenaline in postsynaptic peptidergic neurones. 2. In primary hypothalamic cell cultures and in a hypothalamic neuronal cell line, [3H]-prazosin bound with high affinity and was displaced by unlabelled prazosin in concentrations of 10(-10) to 10(-7) M. However, at concentrations of unlabelled prazosin above 10(-7) M, there was a paradoxical increase in apparent [3H]-prazosin binding. 3. Methoxamine, an alpha 1-adrenoceptor ligand that is not subject to significant neuronal uptake, displaced [3H]-prazosin but did not cause the paradoxical increase in the apparent binding of [3H]-prazosin. Cooling the cells to 4 degrees C reduced the total amount of prazosin associated with the cells; under these conditions, methoxamine almost completely inhibited [3H]-prazosin binding to the cells. 4. In the presence of desipramine (DMI), unlabelled prazosin displaced [3H]-prazosin as before, but no paradoxical increase in apparent binding was seen above 10(-7) M. 5. The paradoxical increase of [3H]-prazosin binding was not observed in membrane preparations of hypothalamic neurones. These findings indicated that the paradoxical increase in apparent [3H]-prazosin binding was due to a cellular uptake process that becomes evident at high concentrations of the ligand. 6. DMI (10(-5) M) had no effect on the specific binding of [3H]-prazosin. The presence of alpha1-adrenoceptors was confirmed by binding of [125]-HEAT, but [3H]-idazoxan (an alpha2- ligand) did not bind to the cells.7. The uptake of prazosin obeyed the Michaelis-Menten model, with similar Km and Vmax values in both types of cultures.8. Noradrenaline was taken up with high affinity by both types of cultures. (+/-)-[3H]-noradrenaline uptake was reduced by DMI and by excluding sodium from the medium, indicating that this process has some of the properties of uptake 1. (+/-)-[3H]-noradrenaline uptake in the cell line was unaffected by testosterone.9. The measured uptake of (-)-noradrenaline in the cell line was considerably increased by blockade of catechol-omicron-methyl-transferase and monoamine oxidase, suggesting that (-)-noradrenaline is metabolized to lipophilic products that escape across the plasma membrane.10. Studies in rats, in which the noradrenaline isomer 6-hydroxydopamine was used, suggested that the post synaptic uptake process is operative in hypothalamic CRH and vasopressin neurones in vivo.11. The Km for (-)-noradrenaline was within the range for the high affinity uptake, process in noradrenergic neurones. Uptake takes place in concentrations at which noradrenaline activates alpha1-adrenoceptors.Removal of noradrenaline from the vicinity of the receptors may prevent desensitization,thus maintaining the responsiveness of postsynaptic neurones to the actions of the neurotransmitter.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-1161049, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-13152692, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-14110752, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-14183431, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-14254430, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-1570341, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-1662384, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-19108208, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-1970822, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2008212, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-202024, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2156676, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2174337, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2196069, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2458397, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2842764, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2845398, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2848090, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2875047, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2885868, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2888036, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-2899848, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-3001461, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-3026691, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-3843705, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-3978416, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-4004111, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-4376244, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-4397955, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-4434209, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-4643454, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-5129345, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-522908, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-5264451, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-5422468, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-5437149, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-5497802, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-5782836, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-5968076, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-5970679, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6120832, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6129044, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6137750, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6277425, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6285, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6321891, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6324813, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6337916, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6514010, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-662024, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6646430, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6669040, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6756545, http://linkedlifedata.com/resource/pubmed/commentcorrection/8358534-6877391
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
109
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
299-307
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
More...